1/188
Looks like no tags are added yet.
Innate immunity
1st-line Bodily defense that is broadly protective against a variety of threats
Examples of innate immunity
Skin
Gastric acid
Mucous secretions
Cilia
Tears
Types of blood cells
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Neutrophils
1st line defense against bacterial and fungal infection
Lymphocytes
Lysis of infected self cell, antivirals (viral illness)
Monocytes
2nd line defense in bacterial infection; targets infection and some cancers
Eosinophils
parasitic infections, hypersensitivity; allergic runs, asthma, parasites, auto-immune conditions
Basophils
allergic response, anti-infective; some cancers
Inflammatory molecules in innate immunity
interferons
prostaglandins
histamine
anti-microbial proteins
ferritin
complement
True or false: inflammatory molecules in innate immune system cause increased vasodilation and vascular permeability
true
Increased vasodilation leads to
increased blood flow to site of injury
Increased vascular permeability leads to
increased WBC penetration to site of injury
Universal signs of inflammation
Fever
Redness
Pain
Swelling
Heat
Adaptive immunity
specificity against one particular threat and long-lasting memory for future exposure.
What two things does adaptive immunity consists of?
T cells and B cells
SLE
systemic lupus erythematosus
systemic autoimmune disease characterized by antibody production and cytokine overproduction
SLE MOA
autoreacive B cells produce antibodies against the body’s own components such as dsDNA
Autoreactive T cells contribute to immune activation and inflammation
Cytokines (inteferons/interlaukins) amplify the inflammatory response
SLE consequences
immune dysregulation, inflammation, and tissue damage leading to symptoms affecting multiple organs, including the skin, joints, kidneys, nervous system, and heart
Anti-DsDNA
lupus nephritis (kidney)
anti-NMDA
CNS complications
Antiphospholipids antibodies (aPL)
Forms a hypercoagulable state → blood more likely to form clots
Thrombosis and pregnancy complications (obstetrics)
APS
antiphospholpipid antibodies syndrome
persistent aPL positivity + clinical manifestations such as thrombosis or pregnancy losses
Low C3/C4
immune dys-regulation → autoantibody production → immune complex formation → complement activation → increased complement consumption → C3/C4 decrease
SLE risk factors
age - young
sex - Female
race - young black women/other non-white
environmental exposures - cigareete, epstein-Barr virus, heavy metals
family history
Greatest mortality risk SLE
men or individuals with adult-onset disease
4 major contrbutors to mortality in SLE
cardiovascular disease
infection
renal complications
malignancies
3 APL antibodies
anticardiolipin
anti-B2GPI
Lupus anticoagulant
Five major presentations of SLE
musculoskeletal lupus
cutaneous lupus
antiphospholipid syndrome
lupus nephritis
CNS lupus
True: lupus arthritis always causes joint destruction
false: usually lupus arthritis does not cause joint destruction while rheumatoid arthritis does
Musculoskeletal lupus
lupus arthritis
sxs: myalgias, arthralgias, arthritis, muscle weakness, chronic fatigue
~90% w/ SLE exp these sxs
cutaneous lupus
Malar butterfly rash; rash across cheeks and bridge of the nose
Photosensitivity: skin sxs that worsen with sunlight exposure
Painless oral ulcers: sores inside the mouth that may go unnoticed because the dont hurt
Alopecia: hair loss
lupus nephritis
manifestation of advanced lupus
When lupus causes inflammation and age to these structures blood and proteins can leak into the urine.
sx: hematuria (blood in urine), proteinuria, increased SCr, increased BUN
true of false: lupus nephritis is diagnosed via sxs
false: lupus nephritis diagnosed officially via kidney biopsy
CNS lupus
manifestation of advanced SLE
anti-NMDA antibodies → CNS complications
sx: HAs, seizures, delirium, mood changes, psychosis
Miscellaneous SLE symptoms
fever without infection (inflammation from lupus itself can cause fever)
weight loss
pancytopenia (Decreased red blood cells, white blood cells, and platelets)
vasculitis (inflammation of blood vessels)
Raynaud’s phenomenon (reduced blood flow to the fingers or toes often triggered by cold or stress)
3 specific criteria of SLE diagnosis according to 2019 EULAR/ACR classification framework
ANA positivity >/= 1:80
Clinical findings at least 1 clinical criterion
EULAR/ACR weighted score >/= 10 points
True or false: having at least 2 of the any 3 criteria classifications checked off allows for SLE diagnosis
False: ANA is an entry criterion for this classification system but a positive alone does not qualify for SLE. We need all three to be diagnosed with SLE
SLE: Non-biologics therapy
Hydroxychloroquine
corticosteroids
SLE: non-biologic immunosuppressants
methotrexate
azathioprine
mycophenolate
cyclosporine
cyclosphamide
voclosporin
SLE biologics
Belimumab
rituximab
anifrolumab
Hydroxychloroquine
Plaquenil
inhibits toll-like receptors (TLRs) and decreases T-cell activation/cytokine production which ultimately reduced lupus-related inflammation
cornerstone of SLE treatment → consider in all pts unless contraindicated
1st line for low-disease activity RA
ADR: N/V, abdominal pain, rash, retinal toxicity
monitoring: eye monitoring - baseline exam and q5yrs after initiation
hydroxychloroquine dosing for RA
200 mg BID or 400 mg QD
Hydrochloroquine dosing for lupus
5mg/kg/day
How long does it take for hydrochloroquine to reach full medical benefit in lupus
3-6 months
True or false: hydroxychloroquine can cause irreversible eye damage
True; retinal toxicity may lead to irreversible damage.
If hydroxychloroquine is for long term use w/o immediate relief, what can be used for acute flare relief
corticosteroids
Corticosteroids: Risk mitigation
bone protection - pts taking prednisone >/=2.5mg/d should receive calcium and vitamin D supplementation
surgery - pts taking chronic corticosteroidss who undergo surgery may require stress-dose steroids
discontinuation - never abruptly d/c chronic corticosteroids therapy
Corticosteroids: acute adverse effects
fluid retention
electrolyte disturbances
increased blood pressure
hyperglycemia
mood changes, insomnia, psychosis
Corticosteroids: chronic effects
immunosuppression
skin thinning and striae
weight gain and atypical fat distribution
osteoporosis
glaucoma
Belimumab
Benlysta
targets B-cell pathway: blocks B-lymphocyte stimulator (BLyS)/BAFF a protein that supports B-cell survival → decreases autoantibody production
dose: IV 10 mg/kg every 4 weeks; SubQ 200 mg 1x/week
Steroid-sparing effect: reduces the need for corticosteroids in treating lupus by helping improve disease control
ADR: infusion rxn, mood disorders, infections
Belimumab and lupus nephritis
Pts with this disease requires at least 2 IV doses before switching to subQ
Anifrolumab
Saphnelo
Type I interferon inhibitor → interferons are cytokines involved in immune signaling which causes inflammation.
most useful in pts with cutaneous lupus → prominent skin manifestations OR steroid-sparing pts who require chronic corticosteroids to control disease activity
Dose: 400 mg IV q4weeks ~300 mg is the FDA approved tho 😛
ADR: infusion rxn, respiratory infection, herpes zoster (increased risk of shingles)
Voclosporin
lupkynis
calcineurin inhibitor → calcineurin activates T-cells promotes production of IL-2, inhibiting it reduces inflammation
for pts with lupus nephritis already receiving mycophenolate and glucocorticoids; its an addition
C/I initiation in pt eGFR <45; BP >165/105
ADR: diarrhea, eGFR decline, HTN, migraines
DDI for voclosporin
CYP3A4 inhibitors/Grapefruit → increases exposure which could be devastating in pts with lupus nephritis
Cyclophosphamide
Cytoxan
alkylating agent that damages DNA to prevent cell proliferation including immune cells responsible for lupus inflammation
last-line treatment for SLE due to substantial immunosuppression and toxicity
C/I: pregnancy
ADR: hemorrhagic cystitis (inflammation/bleeding of the bladder, myelosuppression (reduced production of blood cells in bone marrow), infertility (potential reproductive toxicity)
What can be co-admin with cyclophosphamide to decrease risk of hemorrhagic cystitis
mesna
Rituximab
Rituxan
monoclonal antibody that targets CD20 a protein expressed on the surface of many B-cells to deplete B-cells and reduce autoimmune activity in lupus.
dosing based on body surface area (m2) not kg
ADR: infusion rxn, infection activation/reactivation
premedication before infusion to reduce infusion rxn and screen for TB/hepatitis before initiating
Methotrexate
MTX
antimetabolite that helps decrease inflammation and control symptoms such as lupus-related arthritis
Considered in pts with uncontrolled mucoskeletal lupus → inflammatory joint manifestations
1st line for mod-high disease activity RA
C/I: pregnancy
ADR: elevated LFTs, stomatitis (ulcerations/inflammation in oral mucosa), teratogenic
Should be given with folic acid to reduce side effects such as stomatitis and gastrointestinal toxicity; should screen for hep B/C before starting
Methotrexate dosing for RA
7.5-20 mg weekly
for initial can break down 7.5 mg to 2.5 mg for 3 doses in 1 day
Methotrexate dosing for Lupus
15-25 mg weekly
Azathioprine
Imuran
antimetabolite that inhibits purine synthesis to reduce T and B cell proliferation and reducing immune response
uncontrolled musculoskeletal lupus and pregnant
daily dosing
ADR: myelosuppression (reduced production of red blood cells), hepatotoxicity (LFTs elevation)
Mycophenolate
cellcept, myfortic; MMF/Cellcept (1 g BID) and myfortic (720 mg BID) not interchangeable diff mg dosages
antimetabolite immunosuppressant that interferes with purine synthesis by inhibiting inosine monophosphate dehydrogenase (IMPDH) which prevents T/B cell proliferation and suppresses immune response
Useful in lupus nephritis induction therapy → initial more intensive treatment phase intended to rapidly control active disease “save the kidney, STAT”
ADR: myelosuppression, GI distress, teratogenicity (fetal harm)
SLE treatment pathway
hydroxychloroquine, UV protection, smoking cessation, medication review for potential drug-induced lupus, glucocorticoids depending on disease severity
and use of immunosuppressants like Methotrexate, Azathioprine, or Mycophenolate as needed.
positive antiphospholipid antibodies w/ no hx of thrombosis
consider aspirin
positive antiphospholipid antibodies w/ hx of thrombosis
warfarin
Non-pharm SLE treatment
UV protection
Tobacco avoidance
Exercise
Fertility and SLE
avoid estrogen-contiaing contraceptives in pts with antiphospholipid antibodies → increased risk of thrombosis
Copper IUDs are effective however increase bleeding risk
Progestin-only contraceptives are recommended as safer alternatives for women with SLE → avoids estrogen-related thrombotic concerns
Pregnancy and SLE
high risk pregnancy complications such as preeclampsia, fetal growth restriction, and increased risk of miscarriage due to lupus
hydroxychloroquine (lupus) and low-dose aspirin (preeclampsia)
Drugs that induce lupus
procainamide → high
hydralazine → high
minocycline
isoniazid
TNF inhibitors
How to recognize drug-induced lupus
pt starts med → one month passes → lupus-like sxs → med d/c → sxs improve
SLE Monitoring
monitor sxs and disease activity q4mos → rash, joint inflammation, mood changes, etc
Monitor markers (ANA, autoantibodies, ESR, CRP) q4-12mos
Monitor adherence hydroxychloroquine every encounter
Monitor body weight every encounter
Monitor hydroxychloroquine retinal toxicity q5yrs after initial baseline dilated eye exam
Gout
inflammatory response to monosodium urate deposition in joints
Does purine increase or decrease uric acid
Increase: purine metabolism leads to increased uric acid levels in the blood, potentially causing gout.
Hyperuricemia
uric cid levels >6.8
Uric over-production causes
physiologic purines derived from normal metabolism
dietary intake
tumor lysis sundrome
rare enzyme abnormalities
Uric acid under-excretion
renally eliminated → kidney dysfunction leads to increased serum uric acid
Drug-induced gout
increased purine production: chemotherapy causing tumor lysis, ethanol
Decreased uric acid excretion: loop/thiazide diuretic, calcineurin inhibitors, low-dose salicylate, pyrazinamide, levodopa, insulin, ethanol
True or false: gout and hyperuricemia are the same thing/interchangebale
False; gout is a form of arthritis caused by the accumulation of uric acid crystals causing joint pain, arthritis, inflammation, and joint destruction. Hyperuricemia refers to elevated levels of uric acid in the blood (>6.8), which may not always result in gout.
Acute gout attack
acute onset
lower extremity joint pain
pain frequently begins overnight
generally resolve after 7-14 days even without treatment
may be provoked by alcohol intake, initiation if gout causing drug, purine overconsumption, rapid lowering of serum uric acid
Which body part greatly affected by cut gout atttack
the great toe; often first joint to experience pain/swelling
How is acute gout attack defined?
athrocentesis + synovial fluid analysis with MSU crystals
AND
acute painful symptoms
inter-critical gout
an asymptomatic period between gout attacks
may last years
periods may shorten in progressively worsening disease
Tophaceous gout
large urate crystal deposition in joints
joint destruction
Gout nephropathy
nephrolithasis with urate crystals
acute CKD
Diagnosis: GOUT
definitive diagnosis: synovial fluid aspirate with monosodium urate monohydrate crystals
Clinical diagnosis: recurrent monoarticular joint pain + inflammation + erythema + hyperuricemia
Whats the acute gout diagnosis rule?
not recommended for or against by contemporary guidelines
can be useful to gauge level of concern when clinical picture unclear
Colchicine
MOA: anti-mitotic prevents immune system infiltration into joints and reducing inflammation and pain
ADRs: N/V, diarrhea (GI upset)
Renally eliminated
Colchicine dosing CrCl > 30
Day 1: 1.2 mg x 1 dose + 0.6 mg 1 hr later
Day 2: 0.6 mg BID until flare resolves
Prophylaxis: 0.6 mg BID daily
Colchicine dosing CrCl < 30
1.2 mg x 1 dose + 0.6 mg 1 hr later
Prophylaxis: 0.3 mg QD-daily
Colchicine dosing dialysis
0.3-0.6 mg x 1 dose
Prophylaxis: 0.3 mg 2x/wk
Other gout anti-inflammtories
NSAIDs: indomethacin, naproxen, sulindac
Corticosteroida: prednsone, intra-articular triamcinolone
Gout - NSAIDs
avoid in elderly
Caution in pts with hx. HF, PUD/GI risk, renal dysfunction
Gout - Corticosteroids
caution w/ hx, of diabetes
IA triamcinolone use of confined to 1-2 joints
Xanthine oxidase
urate lowering therapy
allopurinol: less effectuve but cheaper and no CV risk
Febuxostat: more effective than allopurinol but pricier and higher CV risk
Allopurinol
Zyloprim
intial: 100 mg ; eGFR <60 50 mg
Maintenance: 100-800 mg QD
ADR: urticaria, Gi upset, HAs
HLA-B*5801 screening recommended in those of East Asian, African descent
Uricosurics
urate lowering therapy
Probenacib only available agent in the US
CrCl < 50 → decreased efficacy
ADRs: diuresis, nephrolithiasis, icovonveient pill burden, DDIs
C/I in pts with hx of kidney stones
PTP: stay well-hydrated
Pegloticase
Urate lowering therapy
8 mg IV over 2 hours q2wks
ADRs: infusion rxns, wallet toxicity, decreased effectiveness over time, HF exacerbations
Obtain uric acid levels prior to every infusion; if <6 hold dose
Pre-medicate w/ MTX + daily FA x 4 weeks; use anti-histaminess + corticosteroid during infusion
Reserved for severe gout
Which ARB has a benefit for hyperuricemia
losartan